1. Home
  2. ATLX vs ACRV Comparison

ATLX vs ACRV Comparison

Compare ATLX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlas Lithium Corporation

ATLX

Atlas Lithium Corporation

HOLD

Current Price

$2.94

Market Cap

79.3M

Sector

Industrials

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

68.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATLX
ACRV
Founded
2011
2018
Country
Brazil
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.3M
68.5M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
ATLX
ACRV
Price
$2.94
$1.61
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$12.00
$11.67
AVG Volume (30 Days)
320.9K
452.8K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
47.08
15.13
EPS
N/A
N/A
Revenue
$92,491.00
N/A
Revenue This Year
$64,564.67
N/A
Revenue Next Year
$785.59
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$1.20
52 Week High
$8.25
$3.56

Technical Indicators

Market Signals
Indicator
ATLX
ACRV
Relative Strength Index (RSI) 43.04 46.04
Support Level $2.74 $1.58
Resistance Level $3.92 $2.20
Average True Range (ATR) 0.16 0.09
MACD 0.04 -0.02
Stochastic Oscillator 71.70 47.50

Price Performance

Historical Comparison
ATLX
ACRV

About ATLX Atlas Lithium Corporation

Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: